Kathie Ngo1, Mamdouh Aker1, Lauren E Petty1, Jason Chen1, Francesca Cavalcanti1, Alexandra B Nelson1, Sharon Hassin-Baer1, Michael D Geschwind1, Susan Perlman1, Domenico Italiano1, Angelina Laganà1, Sebastiano Cavallaro1, Giovanni Coppola1, Jennifer E Below1, Brent L Fogel1. 1. Department of Neurology (K.J.N., M.A., S.P., G.C., B.L.F.), Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles; Department of Medical Genetics (L.E.P., J.E.B.), Vanderbilt University Medical Center, Nashville, TN; Department of Psychiatry and Biobehavioral Sciences (J.A.C., G.C.), University of California, Los Angeles, CA; Institute of Neurological Sciences (F.C., S.C.), Italian National Research Council, Mangone, Italy; Department of Neurology (A.B.N., M.D.G.), UCSF Memory and Aging Center, University of California, San Francisco; Sackler Faculty of Medicine (S.H.), Tel-Aviv University, Israel; Italian College of General Practitioners and Primary Care (D.I.), Department of Clinical and Experimental Medicine (A.L.), University of Messina, Italy; and the Department of Human Genetics (B.L.F.), David Geffen School of Medicine, University of California, Los Angeles.
Spinocerebellar ataxias (SCAs) are a heterogeneous group of neurodegenerative disorders that involve the degeneration of the cerebellum and brainstem.[1] These genetic diseases are characterized by autosomal dominant inheritance with approximately 44 known subtypes. Recently, dominant mutations in the CACNA1G gene, encoding the voltage-gated calcium channel CaV3.1, have been linked to SCA42 in French[2] and Japanese[3,4] families. SCA42 prevalence elsewhere in the world has yet to be documented. Through a combination of whole-exome sequencing (WES) and linkage analysis, we have identified an SCA42 mutation in patients from 3 additional countries, expanding the worldwide prevalence of this disease.
Methods
All study methods were approved by the Institutional Review Board of UCLA. All patients received a comprehensive clinical evaluation for acquired causes of ataxia.[5] All patients provided written informed consent for collection of DNA. Only patients who tested negative for common genetic ataxias (SCA1, SCA2, SCA3, SCA6, SCA7, and Friedreich ataxia) were enrolled.[5] WES was performed for 8 members of 3 families (figure, A and B). Genomic DNA (gDNA) libraries were prepared using the Nextera Rapid Capture Exome kit (Illumina, San Diego, CA). Sequencing for these libraries was performed with 107-bp paired-end reads on a HiSeq 2500 sequencer in the rapid-run mode platform (Illumina, San Diego, CA). The gDNA library for B-III-3 was prepared using the SureSelect Human All Exon V4 Capture kit (Agilent Technologies, Santa Clara, CA), and 101-bp paired-end reads were sequenced on the Illumina HiSeq 4000 platform (Illumina, San Diego, CA). Sequencing data were processed as described.[5] Linkage analysis was conducted with ALLEGRO on 190,569 single nucleotide polymorphisms (SNPs) (average distance between SNPs ≈ 0.015 Mb) under a dominant model (f0/f1/f2 = 0/1/1) with estimated minor allele frequencies drawn from HapMap3 project[6] Centre d'Etude du Polymorphism Humain - Utah population data, comprised Utah residents with Northern and Western European ancestry.[7] Self-reported ancestry was confirmed via principal component analysis (PCA) of WES variants with a minor allele frequency of >5% and 1000 Genomes Project Phase 3[8] reference data. Segregation analysis for family A was performed by PCR, followed by Sanger sequencing.
Figure
Pedigrees of the SCA42 families identified in this study
(A) Pedigree of family A. (B) Pedigree of family B. Probands are indicated by an arrow. Shaded symbols represent affected individuals. Individuals who had WES are indicated by an asterisk. Genotypes of the c.5144 position in CACNA1G are shown under each patient sequenced. G is the reference, and A is the p. R1715H mutation. Individuals who were unavailable for genotyping are represented in gray with dashed lines. Shaded gray individuals were reported as affected. SCA = spinocerebellar ataxia.
Pedigrees of the SCA42 families identified in this study
(A) Pedigree of family A. (B) Pedigree of family B. Probands are indicated by an arrow. Shaded symbols represent affected individuals. Individuals who had WES are indicated by an asterisk. Genotypes of the c.5144 position in CACNA1G are shown under each patient sequenced. G is the reference, and A is the p. R1715H mutation. Individuals who were unavailable for genotyping are represented in gray with dashed lines. Shaded gray individuals were reported as affected. SCA = spinocerebellar ataxia.
Results
Family A was clinically evaluated in Italy, their country of origin, and PCA confirmed European ancestry. Affected members exhibited pure cerebellar ataxia with onset between ages 22 and 58 years (mean 37.5 years). All affected members initially experienced a subjective sense of leg weakness and imbalance that slowly progressed to gait and limb ataxia with dysarthria. There was no nystagmus, abnormal saccadic pursuit, motor deficits, pyramidal or extrapyramidal signs, abnormal sensation, or cognitive decline noted in any patients. MRI of the brain demonstrated cerebellar atrophy in all patients. WES identified a known pathogenic variant in the CACNA1G gene in all 3 affected family members (A-II-8, A-III-10, and A-III-7) tested. All other dominant SCAs were excluded by linkage analysis and/or by the absence of rare missense variation.[5] The CACNA1G variant (hg19:chr17:48694921G>A, p.Arg1715His) was previously observed in patients from France and Japan.[2-4] This variant was not present in the ExAC (exac.broadinstitute.org) or gnomAD (gnomad.broadinstitute.org) databases of human variation. The variant segregated with disease and was located within a linkage peak, consistent with being pathogenic.In a second family with pure cerebellar ataxia, family B of Eastern European ancestry living in the United States, the proband (B-III-1) developed, at age 67 years, a sense of imbalance that slowly progressed to a gait and limb ataxia with dysarthria. His first cousin once removed (B-IV-1) was also affected, with an age at onset of 39 years, initially also involving his balance and speech and slowly progressing to a gait and limb ataxia with dysarthria. MRI of the brain showed cerebellar atrophy. PCA verified European ancestry. The above CACNA1G variant was identified in both patients by WES. The proband's sister (B-III-3) also carried the variant but reported herself as asymptomatic and was unavailable for neurologic examination.Lastly, WES identified the same variant in a man from Yemen, clinically evaluated in Israel, who, at age 25 years, presented with a sense of imbalance and intermittent jerking movements of his neck that slowly progressed to a tremor with cervical dystonia manifesting as a rightward tilt. His imbalance progressed to a mild gait and lower limb ataxia. The remainder of his neurologic examination was normal. MRI of the brain showed mild cerebellar atrophy, primarily of the vermis. His parents and 6 younger siblings were all reported as asymptomatic; however, none were available for examination or genetic testing. Although the 1000 Genomes Project does not include Yemeni samples, this sample clustered with admixed American samples, indicating primarily European ancestry with small amounts of Asian and African admixture, consistent with expectations for a Middle Eastern population.We next questioned whether CACNA1G variants were common in neurologic disease in the US population, so we reviewed a recent analysis of 3,040 clinical WES cases,[9] comprising 1,082 patients with involvement of the CNS, including cerebellar ataxia, and noted that it did not identify any patients with the p.Arg1715His variant we detected and found only 1 patient with a novel variant in CACNA1G deemed pathogenic, suggesting that the mutation of this gene may be rare in the US population. Next, to assess the prevalence of this disease within a specific US ataxia population, we reviewed WES data from 225 sporadic or familial cases seen at our tertiary referral center at UCLA. Aside from family B, we identified no additional cases. Therefore, we estimate the frequency in our ataxia cohort to be 1 of 225 (0.4%) undiagnosed families.
Discussion
In this report, we describe 3 additional SCA42 families originating from Italy, the United States (via Europe), and Yemen, respectively, expanding the worldwide prevalence of the disorder. In addition, we report a case with the new finding of cervical dystonia, along with tremor, previously reported in another family.[3] Although previously reported in French and Japanese families,[2-4] none of the families in this report had clear evidence of French or Japanese ancestry to the best of our ability to ascertain. Although we find the disorder to be rare in our center's US ataxia population (0.4%, N = 225), we recommend that clinicians broadly consider the possibility of SCA42 in undiagnosed patients with autosomal dominant ataxia, without regard to country of origin.
Authors: David M Altshuler; Richard A Gibbs; Leena Peltonen; David M Altshuler; Richard A Gibbs; Leena Peltonen; Emmanouil Dermitzakis; Stephen F Schaffner; Fuli Yu; Leena Peltonen; Emmanouil Dermitzakis; Penelope E Bonnen; David M Altshuler; Richard A Gibbs; Paul I W de Bakker; Panos Deloukas; Stacey B Gabriel; Rhian Gwilliam; Sarah Hunt; Michael Inouye; Xiaoming Jia; Aarno Palotie; Melissa Parkin; Pamela Whittaker; Fuli Yu; Kyle Chang; Alicia Hawes; Lora R Lewis; Yanru Ren; David Wheeler; Richard A Gibbs; Donna Marie Muzny; Chris Barnes; Katayoon Darvishi; Matthew Hurles; Joshua M Korn; Kati Kristiansson; Charles Lee; Steven A McCarrol; James Nemesh; Emmanouil Dermitzakis; Alon Keinan; Stephen B Montgomery; Samuela Pollack; Alkes L Price; Nicole Soranzo; Penelope E Bonnen; Richard A Gibbs; Claudia Gonzaga-Jauregui; Alon Keinan; Alkes L Price; Fuli Yu; Verneri Anttila; Wendy Brodeur; Mark J Daly; Stephen Leslie; Gil McVean; Loukas Moutsianas; Huy Nguyen; Stephen F Schaffner; Qingrun Zhang; Mohammed J R Ghori; Ralph McGinnis; William McLaren; Samuela Pollack; Alkes L Price; Stephen F Schaffner; Fumihiko Takeuchi; Sharon R Grossman; Ilya Shlyakhter; Elizabeth B Hostetter; Pardis C Sabeti; Clement A Adebamowo; Morris W Foster; Deborah R Gordon; Julio Licinio; Maria Cristina Manca; Patricia A Marshall; Ichiro Matsuda; Duncan Ngare; Vivian Ota Wang; Deepa Reddy; Charles N Rotimi; Charmaine D Royal; Richard R Sharp; Changqing Zeng; Lisa D Brooks; Jean E McEwen Journal: Nature Date: 2010-09-02 Impact factor: 49.962
Authors: Brent L Fogel; Hane Lee; Joshua L Deignan; Samuel P Strom; Sibel Kantarci; Xizhe Wang; Fabiola Quintero-Rivera; Eric Vilain; Wayne W Grody; Susan Perlman; Daniel H Geschwind; Stanley F Nelson Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: Marie Coutelier; Iulia Blesneac; Arnaud Monteil; Marie-Lorraine Monin; Kunie Ando; Emeline Mundwiller; Alfredo Brusco; Isabelle Le Ber; Mathieu Anheim; Anna Castrioto; Charles Duyckaerts; Alexis Brice; Alexandra Durr; Philippe Lory; Giovanni Stevanin Journal: Am J Hum Genet Date: 2015-10-08 Impact factor: 11.025
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962
Authors: Kathie J Ngo; Jessica E Rexach; Hane Lee; Lauren E Petty; Susan Perlman; Juliana M Valera; Joshua L Deignan; Yuanming Mao; Mamdouh Aker; Jennifer E Posey; Shalini N Jhangiani; Zeynep H Coban-Akdemir; Eric Boerwinkle; Donna Muzny; Alexandra B Nelson; Sharon Hassin-Baer; Gemma Poke; Katherine Neas; Michael D Geschwind; Wayne W Grody; Richard Gibbs; Daniel H Geschwind; James R Lupski; Jennifer E Below; Stanley F Nelson; Brent L Fogel Journal: Hum Mutat Date: 2019-11-25 Impact factor: 4.700